Our Website Uses Cookies. We and third parties we work with use cookies to collect information about your internet browsing activities to provide you relevant content and advertising on this and other websites, media and devices you use, and to understand your interests to improve the site. For more information on our use of cookies, please view our full Privacy Statement. Click "OK" to continue.

EMGALITY HOME

FOR CONSUMERS

EPISODIC CLUSTER HEADACHE HOME
HEALTHCARE PROVIDERS HOME

FOR HEALTHCARE PROVIDERS

Emgality Walrus and Jessica Campaign image. For your patients with episodic migraine (4-14 migraine headache days [MHDs] per month), one of these is possible with Emgality<sup>®</sup>. The walrus that went to the moon. The woman who experienced a month of total migraine headache freedom. Emgality can give some patients the chance to be totally migraine-free for a month.<sup>1</sup>

For your patients with 4-14 MHDs per month (EVOLVE-1/EVOLVE-2),

Emgality demonstrated ≥50%, ≥75%, and 100% reductions in the number of monthly MHDs from baseline for a significantly greater mean percentage of patients vs placebo1

Mean percentage of patients meeting defined levels of reduction in monthly MHDs<sup>1</sup>

ap<0.001 vs placebo.

In the REGAIN study, in patients with chronic migraine (≥15 headache days per month), the mean percentage of patients achieving a ≥75% and 100% reduction in monthly MHDs from baseline was not significant vs placebo over Months 1 to 3.1

See study design for EVOLVE-1 and EVOLVE-2

See study design for REGAIN

INDICATION
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Discover additional Emgality data or download savings cards

Reference: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 04JUN2019

Are you a US healthcare provider?

The information contained in this section of Emgality.com is intended for US healthcare providers. Please confirm below.

No

You are now leaving Emgality.com.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

Click “Continue” to leave site or “Return to Emgality.com” to close this window and return to Emgality.com.

Are you a US healthcare provider?

The information contained in this section of Emgality.com is intended for US healthcare providers. Please confirm below.

Design: The approval of Emgality is based on the results of three Phase 3, randomized, multicenter, double-blind, placebo-controlled studies in adult patients (N=2886). EVOLVE-1 and EVOLVE-2 were 6-month trials that enrolled 1773 patients with episodic migraine (defined as 4 to 14 MHDs per month). REGAIN was a 3-month trial, followed by a 9-month open-label extension period, that enrolled 1113 patients with chronic migraine (defined as ≥15 headache days per month, of which at least 8 had the features of migraine).1,2,3,4

Endpoints: In all 3 studies, the primary endpoint was the overall mean change from baseline in the number of monthly MHDs, and key secondary endpoints included response rates (the mean percentages of patients with ≥50%, ≥75%, and 100% reduction from baseline in monthly MHDs), the mean change from baseline in patient functioning as assessed by the Role Function-Restrictive domain of the MSQ v2.1 across Months 4 to 6 for EVOLVE-1 and EVOLVE-2, and at Month 3 for REGAIN, and the overall mean change from baseline in the number of monthly MHDs that acute migraine medication was taken.1

MHD=migraine headache day; MSQ v2.1=Migraine-Specific Quality of Life Questionnaire version 2.1.

Reference: 1. Emgality [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2018. 2. Data on file. Lilly USA, LLC. BSD-GZ-US-0007. 3. Data on file. Lilly USA, LLC. BSD-GZ-US-0008. 4. Data on file. Lilly USA, LLC. BSD-GZ-US-0006.